HALP Score as a New Prognostic Index in Metastatic Renal Cell Cancer

Simple item page
dc.contributor.authorEkinci F.
dc.contributor.authorBalcik O.Y.
dc.contributor.authorOktay E.
dc.contributor.authorErdogan A.P.
dc.date.accessioned2024-07-22T08:04:47Z
dc.date.available2024-07-22T08:04:47Z
dc.date.issued2022
dc.description.abstractObjective: To evaluate prognostic significance of the new index, designed by formulating hemoglobin, albumin, lymphocyte, and platelet (HALP) counts in patients with metastatic renal cell carcinoma (RCC). Study Design: Descriptive study. Place and Duration of Study: Department of Medical Oncology, Celal Bayar University, Manisa, Turkey and Adnan Menderes University, Aydin, Turkey, from January 2014 to April 2020. Methodology: Patients with metastatic RCC and sufficient follow-up data were included in the study as a retrospective cohort. HALP score was calculated as hemoglobin (g/L) × albumin (g/L) levels × lymphocyte count (/L)/platelet count (/L). The cut-off value was determined by examining the area under the ROC curve for the HALP value. The endpoints of this study included overall survival (OS) and progression-free survival (PFS). Results: The mean overall survival (OS) of the patients with low HALP score was 17.7 months (95% CI, 2.21 - 33.18), while the OS of the patients with high HALP score was 89.7 months (95% CI, 55.62 - 123.77) and reached statistical significance (p=0.001). The results of univariate (p = 0.009) and multivariate (p=0.012) analyses were statistically significant as well. Conclusion: The HALP score in metastatic RCC patients was closely related to the prognosis. Worse OS was found in patients with a low HALP score. © 2022 College of Physicians and Surgeons Pakistan. All rights reserved.
dc.identifier.DOI-ID10.29271/jcpsp.2022.03.313
dc.identifier.issn1022386X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12849
dc.language.isoEnglish
dc.publisherCollege of Physicians and Surgeons Pakistan
dc.rightsAll Open Access; Gold Open Access
dc.subjectAlbumins
dc.subjectCarcinoma, Renal Cell
dc.subjectHemoglobins
dc.subjectHumans
dc.subjectKidney Neoplasms
dc.subjectLymphocytes
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectalbumin
dc.subjecthemoglobin
dc.subjectalbuminoid
dc.subjecthemoglobin
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectcancer patient
dc.subjectcancer prognosis
dc.subjectcohort analysis
dc.subjectconfidence interval
dc.subjectcontrolled study
dc.subjectdescriptive research
dc.subjectdiagnostic test accuracy study
dc.subjectfemale
dc.subjectfollow up
dc.subjecthemoglobin albumin lymphocyte and platelet score
dc.subjecthuman
dc.subjectkidney metastasis
dc.subjectlymphocyte count
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmultivariate analysis
dc.subjectoverall survival
dc.subjectplatelet count
dc.subjectprogression free survival
dc.subjectreceiver operating characteristic
dc.subjectretrospective study
dc.subjectscoring system
dc.subjectsensitivity and specificity
dc.subjectstatistical significance
dc.subjectTurkey (republic)
dc.subjectunivariate analysis
dc.subjectkidney tumor
dc.subjectlymphocyte
dc.subjectprognosis
dc.subjectrenal cell carcinoma
dc.titleHALP Score as a New Prognostic Index in Metastatic Renal Cell Cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu